Recent clinical evidence has suggested that COVID-19 may present with ocular symptoms as well as pathological changes in the ocular surface in a minority of patients.21-23 Importantly, work published earlier this year by our group and others has shown the presence of SARS-CoV-2 entry factors ACE2 (angiotensin-converting enzyme 2) and TMPRSS2 (Transmembrane Serine Protease 2) in the superficial corneal, limbal and conjunctival epithelium, which led to suggestions of ocular surface serving as an additional entry gateway and potentially a replicative hub.24,25. This evidence concerns the gene ACE2 and COVID-19.